Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global heart lung machine market size was valued at USD 274 million in 2024. The market is projected to grow from USD 284 million in 2025 to USD 348 million by 2031, exhibiting a CAGR of 3.6% during the forecast period.
A heart lung machine, often referred to as a cardiopulmonary bypass (CPB) pump, is a critical device used in open-heart surgery to temporarily take over the function of the heart and lungs. This allows surgeons to operate on a still and bloodless heart. The machine oxygenates the blood and circulates it throughout the body, maintaining vital organ perfusion while the heart is stopped.
The market's steady growth is driven by the rising global prevalence of cardiovascular diseases, which necessitates an increasing number of complex cardiac surgeries. However, the market faces challenges from the growing adoption of minimally invasive cardiac procedures that can reduce the need for full cardiopulmonary bypass. Furthermore, the market is highly concentrated, with LivaNova (Sorin) holding a dominant revenue share of over 59% and Getinge (Maquet) following with a significant portion of the market.
Rising Prevalence of Cardiovascular Diseases
The global increase in cardiovascular diseases (CVDs), such as coronary artery disease and valvular heart disease, is a primary driver for the heart lung machine market. The World Health Organization identifies CVDs as the leading cause of death worldwide, necessitating a high volume of cardiac surgeries like coronary artery bypass grafts (CABG) and heart valve replacements, all of which require cardiopulmonary bypass support.
Advancements in Minimally Invasive Cardiac Surgery
Technological innovation is propelling market growth, with the development of compact, advanced heart lung machines that support minimally invasive cardiac surgeries (MICS). These systems offer improved safety profiles, reduced priming volumes, and enhanced monitoring capabilities, making complex procedures safer and expanding their use in a broader range of healthcare settings.
The growing acceptance of heart transplants and mechanical circulatory support device implantations, which are entirely dependent on extracorporeal circulation, further solidifies the demand for reliable perfusion technology.
Furthermore, the expansion of healthcare infrastructure in emerging economies and increasing investments in cardiac care centers are creating new avenues for market penetration and adoption of these life-support systems.
MARKET CHALLENGES
High Cost and Complex Operational Requirements
The significant capital investment required for advanced heart lung machines and the associated disposables presents a major challenge, particularly for hospitals in cost-sensitive markets. Moreover, these systems demand highly trained perfusionists and specialized teams for operation, leading to high operational costs and creating a barrier to entry in under-resourced regions.
Other Challenges
Risk of Complications
Despite technological improvements, the use of heart lung machines is associated with risks such as systemic inflammatory response, coagulation disorders, and embolic events. Mitigating these complications requires continuous monitoring and sophisticated protocols, adding layers of complexity to patient management.
Market Saturation in Developed Regions
Mature markets in North America and Europe are characterized by high penetration rates and slower procedural growth, leading to intense competition among established players and pricing pressures that can constrain revenue growth.
Shift Towards Beating-Heart Surgery Techniques
A significant restraint on the market is the growing adoption of off-pump coronary artery bypass (OPCAB) surgery, which does not require the use of a heart lung machine. As surgeons and hospitals strive to reduce the risks associated with cardiopulmonary bypass, the preference for these alternative techniques can limit the volume of procedures utilizing traditional heart lung machines.
Stringent Regulatory Approval Processes
Heart lung machines are classified as high-risk Class III medical devices in many jurisdictions, including the US and Europe. The lengthy and costly regulatory pathways for approval of new systems or significant modifications can delay product launches and innovation, acting as a brake on market expansion.
Expansion in Emerging Economies
Rapidly developing healthcare systems in Asia-Pacific, Latin America, and the Middle East present substantial growth opportunities. Rising disposable incomes, increasing government healthcare expenditure, and a growing burden of cardiovascular diseases in these regions are expected to drive the demand for cardiac surgeries and the necessary supporting equipment.
Integration of Artificial Intelligence and Data Analytics
The integration of AI for real-time monitoring and predictive analytics during cardiopulmonary bypass represents a significant frontier. Next-generation systems that can automate functions, predict adverse events, and personalize perfusion strategies offer a competitive edge and are likely to command premium pricing, creating new revenue streams.
Development of Portable and Compact Systems
There is a growing opportunity in the development of miniaturized, portable heart lung machines for use in emergency transport, hybrid operating rooms, and in situations requiring extracorporeal membrane oxygenation (ECMO). These systems enhance clinical flexibility and can be critical in expanding access to life-support care.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Double Roller Pump Heart Lung Machine represents the leading segment, with its dominance largely attributed to superior performance characteristics that are critical for complex and prolonged surgeries. This system offers enhanced blood flow control, greater hemodynamic stability, and improved safety profiles compared to single-pump alternatives, making it the preferred choice in major cardiac centers. The technology's ability to manage higher perfusion requirements during intricate procedures drives its strategic adoption, while continuous innovation from key manufacturers further solidifies its market position through reliability and advanced features that meet the exacting demands of modern cardiac surgery. |
| By Application |
|
Cardiac Surgery is the unequivocal leading application segment, serving as the primary driver for heart lung machine utilization due to the high volume of open-heart procedures performed globally. The segment's leadership is underpinned by the essential role these machines play in facilitating coronary artery bypass grafts, valve repairs, and other complex cardiac interventions by temporarily taking over cardiopulmonary functions. The established procedural protocols and the critical need for life-support during heart stoppage create a consistent and substantial demand. Furthermore, advancements in surgical techniques and the rising prevalence of cardiovascular diseases are key factors sustaining the segment's dominant market share and continuous growth trajectory. |
| By End User |
|
Hospitals constitute the leading end-user segment, driven by their role as the primary facilities equipped to perform major cardiothoracic surgeries that require perfusion support. Large tertiary care hospitals and academic medical centers possess the necessary infrastructure, multidisciplinary teams, and high patient volumes that justify the capital investment in these sophisticated systems. The concentration of complex surgical cases, emergency capabilities, and comprehensive post-operative care units within hospital settings creates a natural and dominant demand base. The trend towards centralizing specialized cardiac services in large hospitals further reinforces this segment's leadership, as it ensures optimized utilization and access to skilled perfusionists. |
| By Technology |
|
Conventional Systems are the established leaders, characterized by their robust design, proven reliability, and extensive use in operating rooms worldwide. These systems form the backbone of cardiac surgical programs due to their comprehensive functionality, ability to handle a wide range of procedures, and long track record of safety. While newer technologies are emerging, conventional systems benefit from the high degree of clinician familiarity, extensive service and support networks, and lower perceived risk associated with their use. Their dominance is maintained by continuous incremental improvements that enhance user interface and monitoring capabilities, ensuring they remain the workhorse technology for the majority of perfusion centers. |
| By Patient Demographic |
|
Adult Patients represent the leading demographic segment, as the prevalence of acquired cardiovascular diseases such as coronary artery disease and valvular heart disease is highest within this population. The sheer volume of cardiac surgeries performed on adults, driven by lifestyle factors and an aging global population, creates the most substantial demand for heart lung machines. This segment's dominance is further reinforced by the fact that surgical interventions are often the standard of care for many adult cardiac conditions. While pediatric and neonatal perfusion requires highly specialized equipment, the market scale for adult applications is significantly larger, influencing product development, clinical protocols, and overall market dynamics towards meeting the needs of this predominant patient group. |
A Market Dominated by Established Global Leaders
The global Heart Lung Machine market is characterized by a high degree of consolidation, with a few major multinational corporations commanding the majority of the market share. LivaNova PLC, which operates its cardiopulmonary business under the historic Sorin Group brand, stands as the undisputed market leader. The company's deep-rooted heritage and extensive product portfolio have enabled it to capture over half of the global market, with a production share exceeding 57% and a revenue share of more than 59%. Following closely is Getinge AB, operating through its Maquet subsidiary, which holds the second-largest position with approximately 18% of the production volume. This duopoly benefits from strong brand recognition, robust distribution networks, and significant investment in research and development for advanced perfusion systems.
Beyond the top two players, the market includes several other significant competitors that hold important positions through specialized products and strong regional footholds. Medtronic and Terumo CV Group are key global players with comprehensive cardiovascular portfolios that include advanced heart-lung machines. Companies like Braile Biomedica have established a strong presence in emerging markets, particularly in Latin America. In the Asia-Pacific region, local manufacturers such as Tianjin Medical are increasingly influential, catering to the growing demand for cardiac surgeries with cost-effective solutions. Niche players often compete by focusing on innovation in areas like miniaturization, improved biocompatibility, and integrated monitoring systems, though they face significant barriers to entry due to stringent regulatory requirements and the entrenched positions of the market leaders.
List of Key Heart Lung Machine Companies ProfiledLivaNova (Sorin)
Terumo CV Group
Braile Biomedica
Tianjin Medical
Xenios AG (Fresenius Medical Care)
Chalice Medical Ltd.
Jostra (Part of Getinge)
Senko Medical Instrument Mfg. Co., Ltd.
Microport Scientific Corporation
The global heart lung machine market is on a steady growth trajectory, expanding from a valuation of 274 million in 2024 to a projected US$ 348 million by 2031, reflecting a compound annual growth rate (CAGR) of 3.6%. This sustained growth is driven by the critical role these devices play in supporting cardiac and pulmonary functions during complex surgical procedures such as open-heart surgery, lung transplants, and treatments for acute respiratory failure. The consistent demand underpins a stable and predictable market environment for manufacturers and healthcare providers.
Other TrendsDominant Regional Markets
The market exhibits a strong geographic concentration, with North America being the largest sales region, accounting for nearly 36% of the global market share. Europe follows as the second-largest market, holding a 33% share. The Asia-Pacific region, particularly China, Japan, and South Korea, represents the next significant area of market activity and is viewed as a key region for future growth potential due to expanding healthcare infrastructure and surgical volumes.
Consolidated Competitive Landscape
The competitive environment is highly concentrated, dominated by a few major players. LivaNova (Sorin) is the market leader, having produced over 57% of heart lung machine units and commanding a revenue share exceeding 59%. Getinge (Maquet) is the second-largest player, with a production share of approximately 18%. Other significant competitors include Medtronic, Terumo CV Group, Braile Biomedica, and Tianjin Medical, creating a market structure with high barriers to entry.
Product and Application Segmentation TrendsThe market is segmented by product type, with single roller pump and double roller pump heart lung machines available, catering to specific surgical requirements. In terms of application, the primary use remains in cardiac surgery, followed by lung transplant operations and the treatment of acute respiratory failure. This segmentation highlights the device's versatility and essential function across a range of life-supporting cardiothoracic procedures, ensuring its continued relevance in advanced medical care.
Regional Analysis: Heart Lung Machine MarketEurope
Europe represents a highly mature and significant market for heart lung machines, characterized by universal healthcare systems and a strong emphasis on quality patient care. Countries like Germany, the UK, and France are key contributors, with well-established cardiac surgery programs. The market benefits from high levels of standardization in surgical protocols and rigorous training for perfusionists. The regulatory environment, guided by the MDR, ensures that devices meet high safety benchmarks. While budget constraints in some public healthcare systems can influence procurement cycles, the underlying demand for cardiac surgical interventions remains robust due to an aging demographic. There is a noticeable trend towards upgrading existing equipment with more modern, efficient, and patient-friendly systems.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for heart lung machines, driven by improving healthcare access, rising healthcare expenditures, and a growing burden of cardiovascular diseases. Markets such as China, India, and Japan are experiencing rapid expansion of their hospital infrastructure, including the establishment of specialized cardiac care centers. This growth is creating substantial demand for essential medical equipment like heart lung machines. While cost sensitivity remains a key factor, leading to a varied product mix from basic to advanced systems, there is a clear upward trend in the adoption of technologically sophisticated devices. Local manufacturing initiatives in countries like China are also making these systems more accessible, though international players with premium products maintain a strong presence in high-tier hospitals.
South America
The heart lung machine market in South America is developing, with growth primarily concentrated in larger economies such as Brazil and Argentina. The market dynamics are influenced by economic fluctuations and varying levels of public healthcare investment. In major metropolitan areas, private hospitals often feature advanced cardiac surgery units equipped with modern perfusion systems, catering to a growing middle-class population. However, access to such advanced care can be uneven across the region. The market shows potential for growth as governments gradually increase healthcare spending and as medical tourism, particularly for cardiac procedures, gains traction in certain countries, driving demand for reliable medical technology.
Middle East & AfricaMiddle East & Africa offers a diverse landscape for the heart lung machine market. The affluent Gulf Cooperation Council (GCC) countries, such as Saudi Arabia and the UAE, represent high-value markets with state-funded healthcare initiatives aimed at building world-class medical tourism hubs. These regions invest heavily in the latest medical technologies, including advanced heart lung machines. In contrast, much of Africa faces significant challenges, including limited healthcare infrastructure and funding, which constrains market growth. Nonetheless, targeted investments in key urban centers and partnerships with international healthcare providers are slowly improving access to essential cardiac surgical care and the necessary equipment in some parts of the continent.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key marketsp>
Competitive Landscape
Company profiles and market share analysisp>
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potentialfactors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global heart lung machine market was valued at USD 274 million in 2024 and is expected to reach USD 348 million by 2031.
-> Key players include LivaNova (Sorin), Getinge (Maquet), Medtronic, Terumo CV Group, Braile Biomedica, and Tianjin Medical, among others.
-> Key growth drivers include rising prevalence of cardiovascular diseases, increasing complex cardiac surgeries, and technological advancements in cardiopulmonary bypass pumps.
-> North America is the largest market with a sales share of nearly 36%, while Europe follows with a sales share of 33%.
-> Emerging trends include development of minimally invasive procedures, integration of advanced monitoring systems, and increased focus on patient safety protocols.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates